Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 8973 results

  1. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    Discontinued Reference number: GID-TA10917

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

    Technology appraisal guidance
    In development

  4. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Discontinued Reference number: GID-TA11093

    Technology appraisal guidance
    Discontinued

  5. Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure (IPG463)

    Interventional procedures, IPG463 - Issued: August 2013 --> This guidance has been updated and replaced by NICE HealthTech guidance 599.

    Withdrawn guidance

  6. Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus (IPG789)

    We have moved interventional procedures guidance 789 to become HealthTech guidance 723. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    This guidance has been updated and replaced by NICE's highly specialised technologies guidance 34.

    Withdrawn guidance

  8. Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

    This guidance has been updated and replaced by NICE technology appraisal guidance on dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134).

    Withdrawn guidance

  9. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator has been updated and replaced by NICE indicator 324.

    Withdrawn indicator

  10. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    This guidance has been updated and replaced by NICE's technology appraisal guidance 1129.

    Withdrawn guidance

  11. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

    Technology appraisal guidance
    Discontinued

  13. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued Reference number: GID-TA10284

    Technology appraisal guidance
    Discontinued

  14. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued Reference number: GID-TA10298

    Technology appraisal guidance
    Discontinued

  15. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued Reference number: GID-TA10332

    Technology appraisal guidance
    Discontinued